THAC, The Healthy Aging Company, is a French and US-based privately-owned biopharmaceutical company which has the ambition to develop a range of first-in-class drug candidates targeting T2DM and its complications.


THAC aims to change the way patient care and healthy aging are addressed. THAC is primarily focused on Type 2 Diabetes Mellitus (incl. prevention of complications), a condition with still unmet medical needs, as identified by health agencies.


♦ Its pipeline could lead to potential real game changers for patient care and disease management. THAC is primarily focused on Type 2 Diabetes Mellitus, a condition with still unmet medical needs.

THAC envisions that by fighting insulin resistance, the root cause of T2DM, major breakthrough could be achieved for the treatment of T2DM and the prevention of severe related complications such as peripheral neuropathy (e.g. diabetic foot wounds, amputations).

THAC drug candidates have a unique and innovative mechanism of action that targets oxidation and inflammation, which restores the composition of microbiota, and the insulin sensitivity.

THAC drug candidates are intended to delay disease progression, improve patient’s quality of life, delay premature death and prevent T2DM complications ; peripheral neuropathy is a severe complication for which there is no treatment available; e.g., diabetic foot wounds and amputations.

Pre-clinical and clinical data of ALF-5755 published in international peer-review


♦ The co-founders of THAC have a track record in scientific publications with more than 500 all together. Pr Christian Bréchot is a worldwide renowed scientific. Pr Christian Magnan has published more than 130 scientific publications in the metabolism / diabetes field.

♦ In the context of THAC, the unique and innovative mechanism of action of ALF-5755 and all its scientific and clinical results already observed are the object of publications by the founders in high level scientific journals.

Below are the latest publications regarding ALF-5755 and its mechanism of action in the context of T2DM: anti-inflammatory, anti-oxidant, insulin sensitizer, restoration of the microbiota composition …


The lastest scientific publications regarding ALF-5755 (HIP/PAP, alpha-Reg3)

Le Lay, A., Philippe, E., Roth, F., Sanchez-Archidona, A. R., Mehl, F., Denom, J., Prasad, R., Asplund, O., Hansson, O., Ibberson, M., Andreelli, F., Santoro, L., Amouyal, P., Amouyal, G., Brechot, C., Jamot, L., Cruciani-Guglielmacci, C., & Magnan, C. (2022). Regenerating islet-derived protein 3α : A promising therapy for diabetes. Preliminary data in rodents and in humans. Heliyon, 8(7), e09944


 Darnaud M, Dos Santos A, Gonzalez P, Agui S, Lacoste C, Detercke C, De Hertogh G, Valentino E, Bran E, Zheng J, Boisgard R, Neut C, Dubuquoy L, Chiappini F, Samuel D, Lepage P, Guerrieri F, Doré J, Bréchot C, Moniaux N, Faivre J- « Enteric delivery of regeneraing family member 3 apha-Reg alters the intestinal microbiota and controls inflammation in mice with colitis » Gastroenterology 2018 154 (1000).


Nalpas B, Ichaï P, Jamot L, Carbonell N, Rudler M, Mathurin P, Durand F, Gerken G, Manns M, Trautwein C, Larrey D, Radenne S, Duvoux C, Leroy V, Bernuau J, Faivre J, Moniaux N, Bréchot C, Amouyal G, Amouyal P, Samuel D-  « A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver Diseases ». PLoS One. 2016 Mar 16;11(3).

 Haldipur P, Dupuis N, Degos V, Moniaux N, Chhor V, Rasika S, Schwendimann L, le Charpentier T, Rougier E, Amouyal P, Amouyal G, Dournaud P, Bréchot C, El Ghouzzi V, Faivre J, Fleiss B, Mani S, Gressens P – « HIP/PAP prevents excitoxic neuronal death and promotes plasticity ». Ann Clin Transl Neurol. 2014 Oct;1(10):739-54.


 Nicolas Moniaux, Marion Darnaud, Kévin Garbin, Alexandre Dos Santos, Catherine Guettier, Didier Samuel, Gilles Amouyal, Paul Amouyal, Christian Bréchot, Jamila Faivre- « The Reg3α (HIP/PAP) Lectin Suppresses Extracellular Oxidative Stress in a Murine Model of Acute Liver Failure ». PLoS One. 2015 May 4;10(5).


 Moniaux N, Song H, Darnaud M, Garbin K, Gigou M, Mitchell C, Samuel D, Jamot L, Amouyal P, Amouyal G, Bréchot C, Faivre J. Human – « hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein cures fas-induced acute liver failure in mice by attenuating free-radical damage in injured livers ». Hepatology. 2011 Feb;53(2):618-2.


 Lieu HT, Batteux F, Simon FT, Cortes A, Nicco C, Zavata F, Pauoin A., Trahao JG, Soubrane O, Weill B, Bréchot C, Christa – « HIP/PAP accelerates liver regeneration andprotects against acetaminophren injury in mice » – Hepatology 2005.